The ASH 2024 meeting in San Diego brought together over 30,000 attendees to discuss advancements in blood cancers and hematological disorders. Key highlights included new data on treatments for multiple myeloma, such as GSK’s Blenrep and J&J’s Darzalex Faspro. Cell therapies like Arcellx’s anito-cel and Legend Biotech’s Carvykti also showed promising results. In leukemia and lymphoma, Kura Oncology’s ziftomenib and Eli Lilly’s Jaypirca demonstrated positive outcomes. In sickle cell disease, Beam Therapeutics’ gene-editing therapy BEAM-101 and Novo Nordisk’s etavopivat showed potential benefits. Cell therapies targeting GPRC5D and non-Hodgkin lymphoma were also discussed, along with Sanofi’s rilzabrutinib for immune thrombocytopenia and Regeneron’s drug combination for paroxysmal nocturnal hemoglobinuria.
Source link
ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More
